HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- (1- hexylcyclobut- 1- yl)- 6a,7,8,9,10,10a- hexahydro- 6,6- dimethyl- 6H- dibenzo(b,d)pyran- 1,9 diol

structure in first source

Also Known As:

AM 2389; AM-2389; AM2389

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Benzopyrans: 195
      - 3-(1-hexylcyclobut-1-yl)-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo(b,d)pyran-1,9 diol: 5
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - 3-(1-hexylcyclobut-1-yl)-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo(b,d)pyran-1,9 diol: 5

Experts

1.	Nikas, Spyros P: 5 articles (01/2022 - 03/2012)
2.	Bergman, Jack: 3 articles (01/2022 - 01/2013)
3.	Makriyannis, Alexandros: 3 articles (08/2015 - 03/2012)
4.	Iliopoulos-Tsoutsouvas, Christos: 2 articles (01/2022 - 01/2022)
5.	Makriyannis, Alex: 2 articles (01/2022 - 01/2022)
6.	Paronis, Carol A: 2 articles (01/2022 - 01/2013)
7.	Järbe, Torbjörn U C: 2 articles (08/2015 - 03/2012)
8.	Shukla, Vidyanand G: 2 articles (08/2015 - 03/2012)
9.	Tai, Sherrica: 2 articles (08/2015 - 03/2012)
10.	Carlezon, William A: 1 article (01/2022)

Related Diseases

1.	Hypothermia 08/01/2015 - "Repeated administration of AM2389 led to tolerance by attenuating hypothermia that was induced by acute AM2389 administration. " 03/01/2012 - "AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice." 01/01/2013 - "Direct-acting CB1 agonists, including Δ(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia. "
2.	Tremor (Tremors) 01/01/2022 - "Results show that increases in paw tremors occurred following 5-day exposure to AM2389 or Δ9-THC. " 01/01/2022 - "In concurrent work we report that repeated administration of the high-efficacy cannabinoid 1 (CB1) receptor agonist AM2389 to mice for 5 days led to heightened locomotor activity and paw tremor following treatment discontinuation, potentially indicative of spontaneous cannabinoid withdrawal. "
3.	Sleep Deprivation 01/01/2022 - "This pattern persists following AM2389 discontinuation and is accompanied by emergence of sleep fragmentation. "
4.	Catalepsy 08/01/2015 - "The cannabinergic AM2389 was acutely characterized in the tetrad (locomotor activity, analgesia, inverted screen/catalepsy bar test, and temperature), with some comparisons made to Δ(9)-tetrahydrocannabinol (THC). "

Related Drugs and Biologics

1.	CB1 Cannabinoid Receptor (CB1 Receptor)
2.	Dronabinol (THC)
3.	Mesylates (Mesylate)
4.	Ligands
5.	Cannabinoids
6.	9- (hydroxymethyl)- 3- (1- adamantyl)hexahydrocannabinol
7.	(3R)- ((2,3- dihydro- 5- methyl- 3- ((4- morpholinyl)methyl)pyrrolo- (1,2,3- de)- 1,4- benzoxazin- 6- yl)(1- naphthalenyl))methanone (WIN 55,212)

Related Therapies and Procedures

1.	Analgesia